2019 CYIR Finalized
43 ILD ICU REHABILITATION ICU REHABILITATION ICU REHABILITATION ILD Joyce S. Lee, MD University of Colorado Denver Division of Pulmonary Sciences & Critical Care Medicine Aurora, CO TUESDAY, MAY 21 DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. Summary Our understanding of interstitial lung diseases (ILD), includ- ing idiopathic pulmonary fibrosis (IPF), has substantially increased over the past few decades. As our understand- ing of these disease states evolve, the way in which we approach the diagnosis of ILD and IPF should be re- assessed in this context. As such, the 2011 joint guide- lines for the diagnosis of IPF was recently updated by the same societies (ATS, ERS, JRS, ALAT) to incorporate new evidence and refine diagnostic criteria. Using similar methodology as in the past guidelines, they re-defined the imaging criteria to be in line with the Fleischner criteria (also published in 2018 and citation provided below) and provided an updated scanning protocol for high-resolution computed tomography (HRCT) imaging in ILD. Further, they assessed the evidence for 8 clinical questions as it relates to diagnostic modalities including the ascertainment of a complete history (e.g. medications and environmental exposures), serologic testing, bronchoscopy with bron- choalveolar lavage (BAL), surgical lung biopsy, transbron- chial lung biopsy, cryobiopsy, multidisciplinary discussion and serum biomarkers. Comments 1. There is an update to the radiologic criteria and now includes four HRCT categories: definite usual interstitial pneumonia (UIP), probable UIP, indeterminate for UIP, and alternative diag- nosis. 2. Motherhood statements were made with regard to complete history and serologic testing in suspected cases of IPF in order to exclude potential causes of ILD. 3. Recommendations with regard to BAL cellular analysis, surgical lung biopsy, transbronchial lung biopsy, and cryobiopsy were made based on the type of pattern observed on HRCT. 4. A strong recommendation against the measurement of serum biomarkers (MMP-7, SPD, CCL-18, KL-6) was recommended. 5. A conditional recommendation was made for the use of multi- disciplinary discussion for decision-making in IPF. THE ROLE OF GENETICS IN INTERSTITIAL LUNG DISEASE Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, Gonzalez-Perez MI, Mejia M, Buendia-Roldan I, Falfan-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac’h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Liote H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clement A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieude P. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med. 2018;379(23):2209-19. Summary It has been observed that there are phenotypic similarities between rheumatoid arthritis associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF). Given the clinical similarities, this study aimed to look at shared genetic risk between these two diseases, in particular the gain-of-function MUC5B promoter variant rs35705950. Using a discovery population and multi-ethnic replication sample, the authors tested the association of the MUC5B promoter variant in 620 patients with RA-ILD, 614 patients with RA without ILD, and 5448 unaffected controls. The authors report an association between the minor allele of the MUC5B promoter variant and RA-ILD, compared to controls (adjusted odds ratio 3.8, 95% CI 2.8-5.2, P=9.7x10^-17). The MUC5B promoter variant was associated with an increased risk of ILD among patients with RA, particularly among those with the usual intersti- tial pneumonia (UIP) pattern on high-resolution computed tomography (adjusted odds ratio 6.1, 95% CI 2.9-13.1, P=2.5x10^-6). There was no association between the
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw